卡培他滨联合奥沙利铂治疗晚期大肠癌的临床观察

目的观察卡培他滨（希罗达）联合奥沙利铂治疗晚期大肠癌的临床疗效和耐受性。方法经病理证实的Ⅲ期和Ⅳ期大肠癌患者20例,每天口服卡培他滨2000mg/m2,第1～14天;奥沙利铂130mg/m^2,静滴,第1天;每3周为1个治疗周期,连用2个周期以上评价疗效。结果20例患者,其中CR1例,PR7例,NC10例,PD2例,总有效率40.0%。主要不良反应为Ⅰ～Ⅱ度的骨髓抑制、恶心呕吐、腹泻、口腔粘膜炎、感觉神经病变和手足综合征,无严重的化疗相关不良反应。结论卡培他滨联合奥沙利铂治疗晚期大肠癌疗效确切,安全性好,副作用可耐受,是治疗晚期大肠癌的有效方法,值得临床推广。

Effect of combined oxaliplatin and capecitabine chemotherapy on advanced colorectal cancer

Objective To investigate the therapeutic effect and tolerability of capecitabine combined with oxaliplatin on advanced colorectal cancer. Methods Twenty patients with advanced colorectal cancer were treated with oxaliplatin 130mg/m2 intravenously once per week and capecitabine 1000mg/m2 orally twice daily for 14 days. Every 3 weeks was a treatment cycle. The effect was evaluated after two treatment cycles. Result Among 20 patients treated with oxaliplatin and capecitabine, complete response was 1 case and partial response was 7 eases. The total effective rate was 40.0%. Adverse effects were mainly grade Ⅰ～Ⅱ that includes marrow inhibitory, nausea and vomiting, diarrhea, mouth ulcer, peripheral neuritis and hand-foot syndrome. There was no serious chemo-therapy-related adverse effect. Conclusion The combined chemotherapy with oxaliplatin and capecitabine is an effective and better tolerance in treatment of advanced colorectal cancer and well worth clinical application.